Pharmacokinetics and Safety Study of PT010 and PT003 in Healthy Chinese Adult Subjects

NCT03075267 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

96

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Obstructive Pulmonary Disease

Interventions

DRUG: PT010 (BGF MDI) 320/14.4/9.6 µg
DRUG: PT010 (BGF MDI) 160/14.4/9.6 µg
DRUG: PT003 (GFF MDI) 14.4/9.6 µg

Sponsor

Pearl Therapeutics, Inc.